scholarly journals A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients

2011 ◽  
Vol 19 (6) ◽  
pp. 859-863 ◽  
Author(s):  
Haeseong Park ◽  
Gwendolyn L. Parker ◽  
Cecelia H. Boardman ◽  
Monica M. Morris ◽  
Thomas J. Smith
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hot Flashes ◽  
Breast Cancer Patients ◽  
Pilot Phase

scholarly journals FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Peter A Fasching ◽  
Sebastian M Jud ◽  
Maik Hauschild ◽  
Sherko Kümmel ◽  
Martin Schütte ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Patients ◽  
Phase Ii ◽  
Primary Breast Cancer ◽  
Phase Ii Trial ◽  
Breast Cancer Patients ◽  
Randomized Phase Ii

Randomized phase II trial evaluating the efficacy of adding sequential half body irradiation (SHBI) to adjuvant chemotherapy in high-risk breast cancer patients with >10 positive lymph nodes

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 627-627
Author(s):  
M. S. Barsoum ◽  
R. M. Gafar ◽  
M. M. Nazmy ◽  
A. Niazy
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Phase Ii ◽  
Adjuvant Treatment ◽  
Phase Ii Trial ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Positive Lymph Nodes

627 Background: Adjuvant sequential half body irradiation (SHBI) is both interesting as well as scientifically sound approach with proven efficacy in many tumors. Methods: Patients with node positive (≥10) breast cancer were randomized in this phase II trial to receive either 6 cycles of adjuvant cyclophosphamide 500 mg/m2, 5FU 500 mg/m2 and epirubicin 100 mg/m2 followed by postoperative local irradiation (Arm A) versus the same adjuvant treatment plus consolidation SHBI staring 3 weeks after end of adjuvant treatment with upper half 750cGy /5 fractions /1week then one month gap followed by the lower half for the same dose (Arm B) Results: Between November 1999 and November 2000 a total of 70 patients who met the eligibility criteria were enrolled. Arm A (n=35) and arm B (n=35) were almost comparable with the respect to different prognostic factors. There was significant improvement in the disease free survival (DFS) at 5 years in arm B. The DFS was 65±8% in arm B while it was 33±8% in arm A (log-rank test: P =0.0036). In subset analysis the difference is apparent in subgroups of patients with less potential metastatic burden, which are T2 cases and ER positive cases. The DFS at 5 years was 83% in arm B and it was 35% in arm A (P=0.0008) in T2 cases. In the subgroup of patients with ER positive tumors (n=51), the DFS at 4 years was 58% in arm B and it was 25% in arm A (P=0.0072). The complications of the addition of SHBI were mild (grades 2 and 3) and mainly gastrointestinal (vomiting, diarrhea and colic). In both arms of the study there were no life-threatening complications or treatment-related mortality. Conclusions: SHBI was found to be a well-tolerated consolidation regimen with acceptable side effects and it showed significant improvement of the DFS in breast cancer patients with ≥ 10 positive lymph nodes especially in the relative cases with good prognosis (T2-ER positive). This makes it worthy of testing in a phase III trial. No significant financial relationships to disclose.

scholarly journals Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial

2013 ◽  
Vol 45 (6) ◽  
pp. 969-979 ◽  
Author(s):  
Geila Ribeiro Nuñez ◽  
Hélio Pinczowski ◽  
Rebecca Zanellato ◽  
Lívia Tateyama ◽  
Fernanda Schindler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Breast Cancer Survivors ◽  
Phase Ii Trial ◽  
Hot Flashes ◽  
Pilot Phase ◽  
Double Blind

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial

2014 ◽  
Vol 50 (13) ◽  
pp. 2190-2200 ◽  
Author(s):  
Duveken B.Y. Fontein ◽  
Ayoub Charehbili ◽  
Johan W.R. Nortier ◽  
Elma Meershoek-Klein Kranenbarg ◽  
Judith R. Kroep ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document